Telomir Pharmaceuticals (TELO) Competitors $1.97 -0.08 (-3.90%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.03 +0.06 (+3.05%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. TVGN, CRDF, MDWD, URGN, SLRN, PROK, DSGN, GNFT, CGC, and YMABShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Tevogen Bio (TVGN), Cardiff Oncology (CRDF), MediWound (MDWD), UroGen Pharma (URGN), Acelyrin (SLRN), ProKidney (PROK), Design Therapeutics (DSGN), Genfit (GNFT), Canopy Growth (CGC), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors Tevogen Bio Cardiff Oncology MediWound UroGen Pharma Acelyrin ProKidney Design Therapeutics Genfit Canopy Growth Y-mAbs Therapeutics Telomir Pharmaceuticals (NASDAQ:TELO) and Tevogen Bio (NASDAQ:TVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, community ranking, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends. Does the media prefer TELO or TVGN? In the previous week, Tevogen Bio had 6 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 10 mentions for Tevogen Bio and 4 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.56 beat Tevogen Bio's score of 0.48 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telomir Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate TELO or TVGN? Telomir Pharmaceuticals currently has a consensus target price of $15.00, suggesting a potential upside of 661.42%. Tevogen Bio has a consensus target price of $7.10, suggesting a potential upside of 429.85%. Given Telomir Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Telomir Pharmaceuticals is more favorable than Tevogen Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Tevogen Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer TELO or TVGN? Tevogen Bio received 6 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformTelomir PharmaceuticalsOutperform Votes2100.00% Underperform VotesNo VotesTevogen BioOutperform Votes8100.00% Underperform VotesNo Votes Which has preferable valuation and earnings, TELO or TVGN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.42-4.69Tevogen BioN/AN/A-$70KN/AN/A Which has more volatility & risk, TELO or TVGN? Telomir Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -0.69, indicating that its stock price is 169% less volatile than the S&P 500. Is TELO or TVGN more profitable? Tevogen Bio's return on equity of -396.07% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -1,170.58% -832.67% Tevogen Bio N/A -396.07%749.97% SummaryTevogen Bio beats Telomir Pharmaceuticals on 6 of the 11 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.63M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio-3.408.7827.1320.06Price / SalesN/A255.64412.28157.10Price / CashN/A65.8538.2534.64Price / Book98.506.557.064.70Net Income-$16.53M$143.93M$3.23B$247.88M7 Day Performance-1.99%3.84%2.86%2.63%1 Month Performance-21.51%11.20%9.05%6.36%1 Year Performance-64.25%4.18%31.39%14.05% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals2.042 of 5 stars$1.97-3.9%$15.00+661.4%-64.2%$58.63MN/A-3.401High Trading VolumeTVGNTevogen Bio4.005 of 5 stars$1.28-0.8%$7.10+454.7%+53.6%$235.38MN/A0.003Analyst ForecastInsider TradeCRDFCardiff Oncology1.8414 of 5 stars$3.51+4.8%$12.00+241.9%+31.2%$233.51M$587K-3.7320MDWDMediWound1.7844 of 5 stars$21.59-2.9%$31.80+47.3%+26.0%$233.35M$19.21M-7.4480URGNUroGen Pharma4.6856 of 5 stars$5.00+3.3%$23.14+362.9%-44.2%$230.54M$91.87M-1.59200Trending NewsShort Interest ↓High Trading VolumeSLRNAcelyrin2.9816 of 5 stars$2.27flat$9.60+322.9%N/A$229.17MN/A-0.92135Positive NewsPROKProKidney2.4713 of 5 stars$0.78+4.5%$5.00+541.7%-61.4%$228.07M$306K-1.423Positive NewsDSGNDesign Therapeutics0.7089 of 5 stars$4.01-0.2%$4.00-0.2%-3.2%$227.64MN/A-4.7240Positive NewsGap UpGNFTGenfit2.5783 of 5 stars$4.51+5.4%$13.00+188.2%-17.0%$225.48M$67.00M0.00120Positive NewsShort Interest ↓CGCCanopy Growth2.388 of 5 stars$1.21flat$2.00+65.3%-78.6%$222.48M$269.00M-0.323,150Gap UpYMABY-mAbs Therapeutics3.7663 of 5 stars$4.87+2.7%$15.60+220.3%-59.0%$220.53M$88.66M-9.02150Analyst Revision Related Companies and Tools Related Companies Tevogen Bio Alternatives Cardiff Oncology Alternatives MediWound Alternatives UroGen Pharma Alternatives Acelyrin Alternatives ProKidney Alternatives Design Therapeutics Alternatives Genfit Alternatives Canopy Growth Alternatives Y-mAbs Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TELO Stock Free TELO Stock Alerts